Gastroenterology Compliance: ASC + Anesthesia + Pathology Coordination

Gastroenterology practices operate at the intersection of ASC Conditions for Coverage at 42 CFR § 416, CMS anesthesia rules under Pub. 100-04 Chapter 12, in-office pathology under CLIA at 42 CFR Part 493 with Stark and anti-markup overlays, USPSTF screening guidance underpinning preventive-benefit coverage, and the screening-to-diagnostic conversion documentation that drives most colonoscopy audit findings.

What CMS actually requires for a GI practice

For ASC-based endoscopy the Conditions for Coverage at 42 CFR § 416.40 – 416.52 govern governance, infection control, medical staff credentialing, surgical services, and anesthesia services. The anesthesia condition at 42 CFR § 416.42 requires a director of anesthesia services, anesthesia administered only by qualified practitioners, and a pre-anesthesia evaluation, intra-procedure monitoring, and post-anesthesia evaluation for every patient.

For endoscopist-administered moderate sedation in GI endoscopy, Medicare uses HCPCS G0500 for the initial 15 minutes (same physician performing the endoscopy, patient age 5 or older), with CPT 99153 for each additional 15 minutes by an independent trained observer. The 2017 sedation revaluation reduced endoscopy code RVUs to remove the sedation work, making G0500/99153 the current Medicare billing pathway for own-provider moderate sedation. Separate anesthesia services (00811 for lower GI, 00731-00732 for upper GI) furnished by a separate anesthesia professional are billed by that anesthesia provider, subject to medical necessity.

Colorectal cancer screening coverage under Medicare follows USPSTF Grade A recommendations and Pub. 100-04 Chapter 18. Screening colonoscopy uses G0121 (average risk) or G0105 (high risk), with the every-10-year (average risk) or every-2-year (high risk) interval. The screening-to-diagnostic conversion via modifier PT is the critical documentation pivot when polyps are found and removed. iFOBT under HCPCS 82274 is the immunochemical screening test; Cologuard (multitarget stool DNA) was billed under G0464 historically, but CMS discontinued G0464 effective January 1, 2016 and replaced it with CPT 81528 (see CMS transmittal R3848CP), covered at three-year intervals for average-risk patients age 45–85.

In-office pathology, common in larger GI groups, requires CLIA certification matched to the complexity of testing performed. The technical/professional split for surgical pathology (88305-TC for the technical, 88305-26 for the professional read) is billable separately, but the anti-markup rule at 42 CFR § 414.50 caps the practice's allowable payment when the reading is performed by a non-employee non-IDTF contractor. The Stark in-office ancillary services exception at 42 CFR § 411.355(b) applies to the referral relationship.

State scope-of-practice rules layer over propofol administration. Several states restrict propofol to anesthesia professionals (MD/DO anesthesiologist, CRNA, AA under supervision); a few states permit RN-administered propofol under specific protocols. The Conditions for Coverage do not preempt state law; the more restrictive standard controls.

The No Surprises Act prohibits balance billing for out-of-network anesthesia and other ancillary services (including pathology, radiology, neonatology, assistant surgeons, hospitalists, and intensivists) at in-network ASCs and hospitals. The NSA notice-and-consent waiver is not available for these ancillary services at an in-network facility (see DOL/EBSA NSA guidance) — do not paper over out-of-network anesthesia or pathology with a notice-and-consent form. ASCs and anesthesia groups coordinate on the patient-notification process and use the federal IDR pathway for disputed amounts.

The documents you must maintain

A GI compliance binder should produce on demand:

• ASC 855B Medicare enrollment file and Conditions for Coverage policy set
• Director of anesthesia services designation and qualified-practitioner roster
• Pre-anesthesia evaluation, intra-procedure monitoring record, and post-anesthesia evaluation template tied to 42 CFR § 416.42
• Anesthesia QAPI program documentation including reversal-agent inventory, malignant hyperthermia protocol, and difficult-airway plan
• Moderate sedation competency assessment for every endoscopist (G0500/CPT 99153 work — Medicare moderate-sedation pathway for GI endoscopy by the operating physician)
• Screening-vs-diagnostic colonoscopy documentation template, with modifier PT use guidance
• iFOBT and Cologuard ordering criteria tied to USPSTF screening intervals
• Anesthesia-to-procedure billing alignment workflow (G0500/99153 for endoscopist-administered moderate sedation; separate anesthesia codes only for an independent anesthesia professional)
• CLIA certificate for in-office pathology, matched to test complexity (most GI in-office histopathology is moderate or high complexity)
• Surgical pathology TC/PC split documentation including anti-markup rule self-attestation
• Stark in-office ancillary services exception self-attestation for in-office pathology and any in-office DME
• Infection-control program with high-level disinfection log for flexible endoscopes (per SGNA reprocessing standards and AORN guidelines)
• Endoscope reprocessing competency assessment for every reprocessing tech
• Sample tracking from collection through pathology read with chain-of-custody documentation
• No Surprises Act compliance documentation — note that the notice-and-consent waiver is unavailable for ancillary services (anesthesiology, pathology, radiology, neonatology, hospitalists, assistant surgeons, intensivists) at in-network facilities; use the IDR process and held-harmless billing instead
• State-specific propofol protocol documentation aligned with the state scope-of-practice rule

In GI ASC audits we have responded to, the most common finding is anesthesia documentation gaps — specifically, the pre-anesthesia evaluation that is dated but does not include the airway assessment, the ASA classification, or the documented review of medications and allergies.

How audits actually work in gastroenterology

CMS or its ASC accreditor (AAAHC, The Joint Commission, AAAASF) inspects against the Conditions for Coverage. The infection-control program is a recurring finding area in GI ASC inspections — high-level disinfection protocol documentation, reprocessing competency, and the time-tracking between procedure and reprocessing.

MAC TPE audits in GI commonly target:

1. Screening-to-diagnostic conversion documentation. The MAC pulls the procedure note, the pathology report, and the claim. If the polyp was found and removed and the code billed is the diagnostic colonoscopy rather than G0121 with modifier PT, the claim is at risk. The reverse — billing G0121 when the procedure was actually diagnostic from the start — is fraud risk.
2. Anesthesia medical necessity. For routine screening colonoscopy in an average-risk patient with no ASA III+ risk factors, separate MAC anesthesia billing has historically attracted MAC scrutiny. Documentation supporting the anesthesia rationale should appear in the pre-anesthesia evaluation.
3. Repeat colonoscopy interval. Medicare covers screening colonoscopy at defined intervals (10 years average risk, 2 years high risk). A repeat at a shorter interval requires documented justification.
4. iFOBT vs diagnostic fecal testing. iFOBT coded as 82274 for screening must be documented as a screening test on an asymptomatic patient; symptomatic-patient testing falls into diagnostic codes.

RAC audits look at prior payments with extrapolation risk. Repeat-colonoscopy interval and screening-to-diagnostic-conversion mistakes are common RAC targets.

UPIC audits often target self-referral patterns under Stark — particularly when the GI practice owns its pathology lab and the referral pattern shows nearly all biopsies routed to the in-house lab. The UPIC examines whether the Stark in-office ancillary services exception elements are met, including the supervision and the group-practice billing structure.

State ASC inspections vary. California (CDPH licensing under H&S Code §1248), Texas (DSHS under 25 TAC Chapter 135), New York (Article 28 Department of Health), and Florida (Chapter 395, F.S.) each operate distinct ASC licensure and inspection schedules.

What GI ASCs trip over most often, in our experience, is the propofol monitoring documentation when anesthesia is billed separately. The anesthesia record exists but the intra-procedure monitoring elements — sedation level scoring, vital signs at defined intervals, oxygen saturation, end-tidal CO2 where used — are documented inconsistently across the case set.

Common gaps unique to GI practice

• Modifier PT applied to the wrong procedure when polyps are found in multiple locations. Documentation should clarify which polyp drove the conversion.
• Endoscope reprocessing time stamps that don't add up. The MAC and the accreditor look for time between procedure end and reprocessing start; gaps trigger findings.
• Anesthesia pre-eval documented after the procedure. The timestamp on the pre-anesthesia evaluation must precede sedation.
• In-house pathology turnaround documented inconsistently. CLIA expects the test report to include collection date, accession date, and report date.
• Cologuard ordered at intervals shorter than three years without documented rationale.
• CPT 81528 (Cologuard, multitarget stool DNA — replaced G0464 effective January 1, 2016) and G0105/G0121 (colonoscopy) billed in conflicting intervals. Medicare coordinates the coverage interval across stool DNA and colonoscopy.
• Anti-markup rule violated when the in-house pathology read is contracted out at a discount but billed at full fee schedule.
• CRNA supervision documentation missing where state rule requires physician supervision of CRNA anesthesia.
• No Surprises Act consent forms missing for out-of-network anesthesia at in-network ASC scenarios.

Maintenance cadence

• Daily: Endoscope reprocessing log; anesthesia equipment safety check; controlled-substance reconciliation for the anesthesia cart
• Weekly: Anesthesia QAPI case review (any cases with adverse events, oxygen desaturation, prolonged recovery)
• Monthly: Coding audit for screening-vs-diagnostic colonoscopy documentation (sample of 20 cases); anesthesia documentation completeness audit
• Quarterly: ASC governance meeting; infection-control program review; CLIA proficiency testing results review; Stark in-office ancillary services exception self-attestation
• Annually: ASC accreditation reaccreditation planning at 180 days; CLIA certificate renewal; state ASC license renewal; anesthesia QAPI annual report; HIPAA risk analysis
• At every staff onboard: Endoscope reprocessing competency before independent reprocessing; anesthesia personnel credentialing per 42 CFR § 416.42; HIPAA training

State preemption to watch

California — CDPH ASC licensure under H&S Code §1248; CMIA layered on every disclosure; propofol restricted to anesthesia professionals; mandatory CURES query for procedural sedation involving controlled substances.

Texas — DSHS ASC licensure under 25 TAC Chapter 135; HB 300 layered; CRNA scope-of-practice rules under Board of Nursing.

New York — Article 28 Department of Health for ASC licensure; specific propofol administration rules under NYCRR Title 10 Part 405; I-STOP applies to procedural sedation involving controlled substances; New York requires Article 28 status for many GI ASC services.

Florida — ASC licensure under Chapter 395, F.S.; F.A.C. 59A-5 ASC rules; office-based surgery rules under Board of Medicine Rule 64B8-9.009; workers' compensation under F.S. Chapter 440.

How d3rx fits

The d3rx specialty compliance binder maintains the GI module: ASC enrollment file, anesthesia services policy set tied to 42 CFR § 416.42, screening-vs-diagnostic colonoscopy documentation template, modifier PT guidance, infection-control and endoscope reprocessing policy, CLIA certificate tracker for in-office pathology, the surgical pathology TC/PC split self-attestation, Stark in-office ancillary services exception documentation, USPSTF screening interval reference, and No Surprises Act compliance set (including the rule that notice-and-consent is unavailable for ancillary anesthesia/pathology at in-network ASCs). It is a source-grounded administrative documentation aid. See the compliance binder overview or the audit defense surface for how the GI module integrates with the broader binder.

D3rx compliance guides are administrative documentation aids. They do not certify compliance, provide legal advice, replace counsel, or guarantee an audit outcome. The practice remains responsible for reviewing, adopting, and maintaining its compliance program.